We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TXRH:NASDAQTexas Roadhouse, Inc. Analysis

Data as of 2026-05-06 - not real-time

$159.69

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Texas Roadhouse is trading at $159.69, just below its 20‑day SMA of 160.76 and well under the 50‑day (166.68) and 200‑day (172.39) averages, signaling short‑term weakness despite a bullish MACD histogram and a modestly neutral RSI of 45.7. Volume is on the rise and the stock sits above the identified support level of 153.83, giving a technical floor, while resistance sits near 167.54. Recent headlines note an upcoming Q1 earnings release on May 7 and a brief rally tied to a two‑week reprieve in the Iranian conflict, adding short‑term momentum drivers. On the fundamentals side, the company posts solid cash generation (operating cash flow > $730 M), a healthy ROE of 29%, and a sustainable dividend yield of 1.9% with a payout ratio under 45%. However, the market valuation is starkly out of line with a DCF‑derived fair value of just $30.9, implying an overvaluation of more than 400% and a downside potential of over 20% despite a modest upside estimate. The modest 3.1% revenue growth, a PE of 26.2, and a beta of 0.68 suggest limited upside in a high‑volatility (27% 30‑day) consumer‑cyclical environment. In sum, the stock offers a technically supported near‑term entry point but faces a substantial valuation gap that dominates the longer‑term outlook.
Investors should weigh the strong cash flow, dividend stability, and short‑term technical bounce against the high valuation premium, cyclical exposure, and elevated volatility. The consensus “Buy” recommendation from analysts aligns with the dividend appeal, yet the extreme overvaluation and sector risk counsel caution, especially for longer horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Bullish MACD histogram with price above support
  • Increasing volume indicating accumulation
  • Upcoming earnings release providing catalyst

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong operating cash flow and dividend sustainability
  • Persistent overvaluation relative to DCF
  • Moderate revenue growth in a cyclical sector

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Fair value gap of >400% suggesting large downside risk
  • High volatility and beta indicating price swings
  • Consumer‑cyclical exposure increasing economic sensitivity

Key Metrics & Analysis

Financial Health

Revenue Growth3.10%
Profit Margin6.90%
P/E Ratio26.2
ROE29.02%
ROA8.81%
Debt/Equity65.92
P/B Ratio7.2
Op. Cash Flow$730.1M
Free Cash Flow$189.8M

Technical Analysis

TrendBearish
RSI45.7
Support$153.83
Resistance$167.54
MA 20$160.76
MA 50$166.68
MA 200$172.39
MACDBullish
VolumeIncreasing
Fear & Greed Index90.38

Valuation

Fair Value$30.92
Target Price$193.60
Upside/Downside21.24%
GradeOvervalued
TypeBlend
Dividend Yield1.90%

Risk Assessment

Beta0.68
Volatility27.21%
Sector RiskHigh
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.